The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Alliance A032002 (ART): Phase II randomized trial of atezolizumab versus atezolizumab and radiation therapy for platinum-ineligible/refractory metastatic urothelial cancer.
 
Himanshu Nagar
Employment - Weill Cornell Medical College
Research Funding - Lantheus Medical Imaging (Inst); ViewRay (Inst)
Other Relationship - Boston Scientific; Lantheus Medical Imaging; Myovant Sciences; Palette Life Sciences; Pfizer; ViewRay
 
Karla V. Ballman
Consulting or Advisory Role - Agenus; Takeda
Patents, Royalties, Other Intellectual Property - Prostate cancer signature patent (Inst)
Expert Testimony - Janssen Oncology; Janssen Oncology; Mylan; Sanofi
 
Scott T. Tagawa
Consulting or Advisory Role - 4D Pharma; Abbvie; AIkido Pharma; Amgen; Astellas Pharma; Bayer; Blue Earth Diagnostics; Clarity Pharmaceuticals; Clovis Oncology; Convergent Therapeutics; Dendreon; Endocyte; Genentech; Genomic Health; Gilead Sciences; Immunomedics; Janssen; Karyopharm Therapeutics; Medivation; Myovant Sciences; Novartis; Pfizer; POINT Biopharma; QED Therapeutics; Sanofi; Seagen; Telix Pharmaceuticals; Tolmar
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Dendreon (Inst); Endocyte (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Inovio Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Newlink Genetics (Inst); Novartis (Inst); POINT Biopharma (Inst); Progenics (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - Patent Royalty from Immunomedics / Gilead
Travel, Accommodations, Expenses - Amgen; Immunomedics; Sanofi
(OPTIONAL) Uncompensated Relationships - ATLAB Pharma; Phosplatin Therapeutics
 
Alan Tan
Stock and Other Ownership Interests - Adaptimmune; Aprea AB; Bluebird Bio; crispr therapeutics; Editas Medicine; FATE Therapeutics; Geron; Iovance Biotherapeutics; Jounce Therapeutics; MEI Pharma; Myovant Sciences; Nektar; Sangamo Therapeutics
Honoraria - AstraZeneca; Bristol Myers Squibb Foundation; Verastem
Consulting or Advisory Role - Exelixis; Foundation Medicine
Speakers' Bureau - AstraZeneca; bristol myers squibb; verastem
 
Bishoy Morris Faltas
Honoraria - Digital Science Press
Consulting or Advisory Role - Guardant Health; Immunomedics; Immunomedics; Merck; QED Therapeutics; QED Therapeutics; Seagen; Seagen
Research Funding - Lilly
Patents, Royalties, Other Intellectual Property - Patent royalties/Immunomedics
 
Arshin Sheybani
No Relationships to Disclose
 
Shiva Baghaie
No Relationships to Disclose
 
Lawrence Howard Schwartz
No Relationships to Disclose
 
David E. Kozono
Honoraria - Reflexion Medical
Consulting or Advisory Role - Genentech
 
Jeffrey A Bogart
Stock and Other Ownership Interests - Cardan Robotics; Verve Medical
 
Olivia Conway
Employment - Epic Systems (I)
 
Gina L. Mazza
No Relationships to Disclose
 
Ronald C. Chen
Consulting or Advisory Role - Abbvie; Accuray; Accuray; Astellas Pharma; Bayer; Blue Earth Diagnostics; Genentech; Janssen; Medivation/Astellas; Myovant Sciences; Pfizer
Research Funding - Accuray
 
Andrew Leonard Laccetti
Consulting or Advisory Role - Bayer; Bayer; Guidepoint Global; Third Bridge
 
Jonathan E. Rosenberg
Honoraria - Clinical Care Options; EMD Serono; Medscape; MJH Life Sciences; Peerview; Pfizer; Physicans' Education Resource; Research To Practice; UpToDate
Consulting or Advisory Role - Alligator Bioscience; Astellas Pharma; AstraZeneca/MedImmune; Bayer; BioClin Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Hengrui Pharmaceutical; Immunomedics; Imvax; Infinity Pharmaceuticals; Janssen Oncology; Lilly; Merck; Mirati Therapeutics; Pfizer/EMD Serono; Pharmacyclics; QED Therapeutics; Roche/Genentech; Seagen; Tyra Biosciences
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech/Roche (Inst); QED Therapeutics (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Predictor of platinum sensitivity (Inst)
 
Michael J. Morris
Stock and Other Ownership Interests - Doximity
Consulting or Advisory Role - Amgen; AstraZeneca; Clarity Pharmaceuticals; Convergent Therapeutics; Daiichi; Exelixis; ITM Isotope Technologies Munich; Lantheus Medical Imaging; NCCN; Pfizer
Research Funding - Bayer (Inst); Celgene (Inst); Corcept Therapeutics (Inst); Janssen (Inst); Novartis (Inst); Progenics (Inst); Roche/Genentech (Inst)
(OPTIONAL) Uncompensated Relationships - Bayer; Janssen Oncology; Novartis